1. Baldwin DS, Montgomery SA, Nil R, Lader M (2007) Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 10:73–84
2. Bandelow B, Baldwin D, Abelli M, Bolea-Alamanac B, Bourin M, Chamberlain SR, Cinosi E, Davies S, Domschke K, Fineberg N, Grünblatt E, Jarema M, Kim YK, Maron E, Masdrakis V, Mikova O, Nutt D, Pallanti S, Pini S, Ströhle A, Thibaut F, Vaghi MM, Won E, Wedekind D, Wichniak A, Woolley J, Zwanzger P, Riederer P (2016) Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry 18:162–214
3. Bandelow B, Wiltink J, Alpers GW, Benecke C, Deckert J, Eckhardt-Henn A, Ehrig C, Engel E, Falkai P, Geiser F, Gerlach AL, Harfst T, Hau S, Joraschky P, Kellner M, Köllner V, Kopp I, Langs G, Lichte T, Liebeck H, Matzat J, Reitt M, Rüddel HP, Rudolf S, Schick G, Schweiger U, Simon R, Springer A, Staats H, Ströhle A, Ströhm W, Waldherr B, Watzke B, Wedekind D, Zottl C, Zwanzger P, Beutel ME (2014) S3-Leitlinie Behandlung von Angststörungen. http://www.awmf.org/leitlinien/detail/II/051-028 (Stand: 15.04.2014 (Revision in Überarbeitung)). Zugegriffen: 15.10.2020
4. Bandelow B (2020) Current and novel psychopharmacological drugs for anxiety disorders. In: Kim YK (Hrsg) Anxiety disorders. Advances in experimental medicine and biology, Bd. 1191. Springer, Singapore
5. Black N, Stockings E, Campbell G, Tran LT, Zagic D, Hall WD, Farrell M, Degenhardt L (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6:995–1010